奥星生命科技(06118.HK)发盈喜，预期2025年度股东应占溢利不少于3000万元

Group 1 - The company, Aoxing Life Science Technology (06118.HK), expects to achieve a profit attributable to shareholders of not less than RMB 30 million for the year ending December 31, 2025, compared to an estimated profit of approximately RMB 16 million for the year ending December 31, 2024 [1][1][1] - As of February 6, 2026, Aoxing Life Science Technology's stock closed at HKD 0.8, down 4.76%, with a trading volume of 122,000 shares and a turnover of HKD 98,700 [1][1][1] - The company has a market capitalization of HKD 431 million and ranks 25th in the medical device II industry [1][1][1]